Senseonics Holdings
Market Cap
US$203.5m
Last Updated
2019/12/07 00:49 UTC
Data Sources
Company Financials +
Executive Summary
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe.
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -14.7% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Mediocre balance sheet with limited growth.
Similar Companies
Share Price & News
How has Senseonics Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SENS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-4.8%
SENS
0.04%
US Medical Equipment
-0.3%
US Market
1 Year Return
-66.8%
SENS
25.0%
US Medical Equipment
18.6%
US Market
Return vs Industry: SENS underperformed the US Medical Equipment industry which returned 25% over the past year.
Return vs Market: SENS underperformed the US Market which returned 18.6% over the past year.
Shareholder returns
| SENS | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.8% | 0.04% | -0.3% |
| 30 Day | -13.9% | 5.3% | 2.2% |
| 90 Day | -10.0% | 3.5% | 5.6% |
| 1 Year | -66.8%-66.8% | 26.0%25.0% | 21.1%18.6% |
| 3 Year | -69.7%-69.7% | 92.8%87.1% | 45.6%36.2% |
| 5 Year | n/a | 124.7%100.4% | 71.1%52.2% |
Price Volatility Vs. Market
How volatile is Senseonics Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Can We See Significant Insider Ownership On The Senseonics Holdings, Inc. (NYSEMKT:SENS) Share Register?3 weeks ago | Simply Wall St
Earnings Update: Senseonics Holdings, Inc. Just Reported And Analysts Are Trimming Their Forecasts1 month ago | Simply Wall St
Why Senseonics Holdings, Inc.'s (NYSEMKT:SENS) CEO Pay Matters To YouValuation
Is Senseonics Holdings undervalued compared to its fair value and its price relative to the market?
7.95x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SENS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SENS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SENS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: SENS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SENS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SENS is overvalued based on its PB Ratio (7.9x) compared to the US Medical Equipment industry average (4.2x).
Next Steps
Future Growth
How is Senseonics Holdings forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
-14.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SENS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SENS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SENS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SENS's revenue (47.4% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: SENS's revenue (47.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SENS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Senseonics Holdings performed over the past 5 years?
-32.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SENS is currently unprofitable.
Growing Profit Margin: SENS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SENS is unprofitable, and losses have increased over the past 5 years at a rate of -32% per year.
Accelerating Growth: Unable to compare SENS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SENS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).
Return on Equity
High ROE: SENS has a negative Return on Equity (-344.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Senseonics Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: SENS's short term assets ($161.6M) exceed its short term liabilities ($22.0M).
Long Term Liabilities: SENS's short term assets ($161.6M) exceed its long term liabilities ($119.7M).
Debt to Equity History and Analysis
Debt Level: SENS's debt to equity ratio (356.2%) is considered high.
Reducing Debt: SENS's debt to equity ratio has increased from 98.3% to 356.2% over the past 5 years.
Balance Sheet
Inventory Level: SENS has a low level of unsold assets or inventory.
Debt Coverage by Assets: SENS's debt is covered by short term assets (assets are 1.8x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SENS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SENS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -43% each year
Next Steps
Dividend
What is Senseonics Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate SENS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SENS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SENS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SENS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SENS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Senseonics Holdings's salary, the management and board of directors tenure and is there insider trading?
0.8yrs
Average management tenure
CEO
Tim Goodnow (57yo)
4yrs
Tenure
US$2,171,443
Compensation
Dr. Timothy T. Goodnow, also known as Tim, Ph.D., has been the Chief Executive Officer, President and Director of Senseonics Holdings, Inc. since December 2015. Dr. Goodnow served as the Chief Executive Of ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD2.17M) is above average for companies of similar size in the US market ($USD1.13M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
0.8yrs
Average Tenure
48yo
Average Age
Experienced Management: SENS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Age and Tenure
4.0yrs
Average Tenure
60yo
Average Age
Experienced Board: SENS's board of directors are considered experienced (4 years average tenure).
Insider Trading
Insider Buying: SENS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 88,500 |
| Max Price | US$1.10 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.6%.
Management Team
Jon Isaacson (48yo)
- Tenure: 0.08yrs
Tim Goodnow (57yo)
President
- Tenure: 4yrs
- Compensation: US$2.17m
Fran Kaufman (68yo)
Chief Medical Officer & Director
- Tenure: 0.08yrs
Mukul Jain (46yo)
Chief Operating Officer
- Tenure: 2.9yrs
- Compensation: US$1.38m
Nick Tressler (46yo)
Chief Financial Officer
- Tenure: 0.08yrs
Board Members
Doug Roeder (48yo)
Non-Management Director
- Tenure: 4yrs
- Compensation: US$158.73k
Ed Fiorentino (60yo)
Non-Management Director
- Tenure: 4yrs
- Compensation: US$155.63k
Stephen DeFalco (57yo)
Chairman
- Tenure: 4yrs
- Compensation: US$172.25k
Tim Goodnow (57yo)
President
- Tenure: 4yrs
- Compensation: US$2.17m
Fran Kaufman (68yo)
Chief Medical Officer & Director
- Tenure: 0.08yrs
Michael Helmus (65yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
Doug Prince (65yo)
Non-Management Director
- Tenure: 4yrs
- Compensation: US$164.88k
Peter Klein (41yo)
Non-Management Director
- Tenure: 4yrs
- Compensation: US$155.63k
James Anderson (78yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
Michael Pishko
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Senseonics Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Senseonics Holdings, Inc.
- Ticker: SENS
- Exchange: AMEX
- Founded: 1996
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$203.453m
- Shares outstanding: 203.45m
- Website: https://www.senseonics.com
Number of Employees
Location
- Senseonics Holdings, Inc.
- 20451 Seneca Meadows Parkway
- Germantown
- Maryland
- 20876
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SENS | AMEX (NYSE MKT LLC) | Yes | New Common Stock | US | USD | Dec 2015 |
| 6L6 | DB (Deutsche Boerse AG) | Yes | New Common Stock | DE | EUR | Dec 2015 |
Biography
Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/07 00:49 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.